Some long-term COVID patients still have the virus in their blood; Paxlovid rebound patients may require prolonged treatment

By Nancy Lapid

(Reuters) – The following is a summary of recent research on COVID-19. They include studies that require additional research to confirm the findings and have not yet been confirmed by expertise.

Some long-term COVID patients still have the virus in their blood

Some long-term cases of COVID may be a response of the immune system to a hidden SARS-CoV-2 infection in one part of the body, new findings from a small study suggest.

Over time, the researchers analyzed several plasma samples collected from 63 patients with COVID-19, including 37 people who developed COVID-19 over a long period of time. In the majority of patients with chronic COVID, the surface protein of the virus was detected within 12 months, and was not present in the plasma samples of asymptomatic patients. In an article published on medRxiv, the researchers may explain that the circulating protein “is a reservoir of the active virus in the body.” peer review. In this study, it may be unclear exactly where the reservoir is. The researchers said they found the active virus in the children’s gastrointestinal tract a few weeks after the initial coronavirus infection, while other researchers found genetic evidence of the virus “in several anatomical locations up to seven months after the onset of symptoms.”

If the results are confirmed by large studies, the presence of spike protein in the blood long after the initial infection may be one way to make a long-term diagnosis of COVID, the researchers said.

Paxlovid “rebound” patients may require prolonged treatment

Recurrence of reported symptoms in some COVID-19 patients who received a five-day course of Pfaiser antiviral Paxlovid tablets may be the result of inadequate treatment, according to researchers who closely evaluated one such patient.

Tests have shown that if taken within five days after the onset of symptoms, COXID-19 can reduce the risk of hospitalization and death in dangerous patients by 89%. However, in some patients, virus levels and symptoms rose again after completing a course of Paxlovid, raising concerns that the options would resist treatment with both drugs or that the pills might somehow weaken patients ’antibody resistance. However, when researchers isolated Omicron BA.2 from a re-raised patient and tested it in laboratory experiments, they found that they were still sensitive to Paxlovid and that there were no mutations that reduced the drug’s effectiveness. They also found that their patient’s antibodies could prevent the virus from entering new cells and infecting them.

The recurrence of COVID-19 symptoms after treatment with paxlovid is likely due to a lack of drugs that prevent infected cells from completely replicating the virus, the researchers said in an article published Monday in Clinical Infectious Diseases https: / / article / doi / 10.1093 / cid / ciac496 / 6611663. Also, the drug can be metabolized or recycled at different speeds in different people, or some people have to take it for more than five days.

After COVID-19, children have more symptoms but less anxiety

Researchers from Denmark reported Wednesday in The Lancet Child & Adolescent Health that persistent health problems in children after COVID-19 were slightly higher than in children of similar ages who were protected from the virus. lanchi / article / PIIS2352-4642 (22) 00154-7 / full text. However, the researchers found that children without COVID-19 had higher levels of anxiety.

They reported that 40% of infants and infants with COVID-19 and 27% of their uninfected peers had at least one symptom for more than two months. Among children aged 4 to 11 years, persistent symptoms were observed in 38% with and without COVID-19. Among 12- to 14-year-olds, 46% of patients with COVID-19 and 41% of those without it have chronic symptoms. The results are based on a survey of about 11,000 mothers of infected children and about 33,000 mothers of uninfected children.

Symptoms associated with chronic COVID-related headaches, mood swings, abdominal pain, and fatigue were more common in healthy children, while chronic symptoms in infected children and new symptoms appeared in one-third after COVID-19. Surprisingly, researchers found that children with COVID-19 experienced fewer psychological and social problems than those in the control group. They suggest that uninfected children may have “limited daily lives to protect themselves from the virus for fear of an unknown disease.”

Click on the Reuters chart for available vaccines for

(Report by Nancy Lapid; edited by Bill Berkrot)

Leave a Comment

Your email address will not be published.